Risk factors for kidney disorders in patients with type 2 diabetes at high cardiovascular risk: An exploratory analysis (DEVOTE 12). (December 2020)

• Record Type: Journal Article
• Authors: Amod, Aslam; Buse, John B; McGuire, Darren K; Pieber, Thomas R; Pop-Busui, Rodica; Pratley, Richard E; Zinman, Bernard; Hansen, Marco Bo; Jia, Ting; Mark, Thomas; Poulter, Neil R
• Is Part Of: Diabetes & vascular disease research. Volume 17:Number 6(2020:Nov.)
• Publication Date: 2020-12
• Subjects: Cardiovascular -- chronic renal failure -- CVOT -- diabetic kidney disease -- type 2 diabetes mellitus -- insulin analogues; Diabetic angiopathies -- Periodicals; 616.462005
• DOI: 10.1177/1479164120970933
• Languages: English
• ISSNs: 1479-1641

Abstract

Aim: To investigate risk factors associated with kidney disorders in patients with type 2 diabetes (T2D) at high cardiovascular (CV) risk. Methods: In DEVOTE, a cardiovascular outcomes trial, 7637 patients were randomised to insulin degludec (degludec) or insulin glargine 100 units/mL (glargine U100), with standard of care. In these exploratory post hoc analyses, serious adverse event reports were searched using Standardised MedDRA ® Queries related to chronic kidney disease (CKD) or acute kidney injury (AKI). Baseline predictors of CKD, AKI and change in estimated glomerular filtration rate (eGFR) were identified using stepwise selection and Cox or linear regression. Results: Over 2 years, eGFR (mL/min/1.73 m 2 ) decline was small and similar between treatments (degludec: 2.70; glargine U100: 2.92). Overall, 97 and 208 patients experienced CKD and AKI events, respectively. A history of heart failure was a risk factor for CKD (hazard ratio [HR] 1.97 [95% confidence interval [CI] 1.41; 2.75]) and AKI (HR 2.28 [95% CI 1.64; 3.17]). A history of hepatic impairment was a significant predictor of CKD (HR 3.28 [95% CI 2.12; 5.07]) and change in eGFR (estimate: −8.59 [95% CI −10.20; −7.00]). Conclusion: Our findings indicate that traditional, non-modifiable risk factors for kidney disorders apply to insulin-treated patients with T2D at high CV risk. Trial registration: NCT01959529 (ClinicalTrials.gov).